Pinoy scientist battles world's top killer disease
Filipino scientist Dr. Cymbeline Tancongco Culiat Photo courtesy of Nell One Therapeutics Inc.MANILA, Philippines - In 2005, cardiovascular diseases that include heart attacks and strokes killed about 17.5 million people. This is 30 percent of global deaths, according to the World Health Organization, and the numbers aren't dwindling.
But if all things go well, a Filipino scientist may triumph over the world’s top killer.
Dr Cymbeline Tancongco Culiat is seeing to it that the trend ends soon so that people around the world suffering from these diseases will be given the chance to lead normal lives.
Her groundbreaking research into molecular genetics can potentially change the face of medicine. Dr Tancongco Culiat is the lead researcher of NellOne Therapeutics Inc., a regenerative medicine company launched this month. The firm seeks to develop treatment and restoration of muscles damaged by heart attacks.
“The promise of restoring both normal tissue mass and function comes from leveraging a critical natural cell growth and maturation pathway," said Dr Tancongco Culiat in an article for Battelle Ventures, one of the companies funding the research.
“It’s not just cell regrowth that is important, but also the way cells are organized to support organ function."
It is a daunting task—there is currently no medicine that can do what Dr Tancongco Culiat seeks to achieve.
“Current approaches, such as those based on stem cells, have shown the potential to restore tissue mass, but with only limited recovery of function," said acting NellOne CEO and Battelle Vantures General Partner Tracy Warren in the same article.
Heart attacks are usually recurrent, so if Dr Tancongco Culiat succeeds in her new undertaking, the product of her research will be the first medicine in the market that can do the most improvement to damaged heart tissues.
The potential is massive, and major institutions have invested an initial $1.5 million to fund Dr Tancongco Culiat’s work. NellOne Therapeutics, Inc. is a joint venture of Battelle Ventures, the University of Tennessee, and Oak Ridge National Laboratory (ORNL) which is under the United States Department of Energy.
JOANNA CAMILLE SISANTE, GMANews.TV
Filipino scientist Dr. Cymbeline Tancongco Culiat Photo courtesy of Nell One Therapeutics Inc.MANILA, Philippines - In 2005, cardiovascular diseases that include heart attacks and strokes killed about 17.5 million people. This is 30 percent of global deaths, according to the World Health Organization, and the numbers aren't dwindling.
But if all things go well, a Filipino scientist may triumph over the world’s top killer.
Dr Cymbeline Tancongco Culiat is seeing to it that the trend ends soon so that people around the world suffering from these diseases will be given the chance to lead normal lives.
Her groundbreaking research into molecular genetics can potentially change the face of medicine. Dr Tancongco Culiat is the lead researcher of NellOne Therapeutics Inc., a regenerative medicine company launched this month. The firm seeks to develop treatment and restoration of muscles damaged by heart attacks.
“The promise of restoring both normal tissue mass and function comes from leveraging a critical natural cell growth and maturation pathway," said Dr Tancongco Culiat in an article for Battelle Ventures, one of the companies funding the research.
“It’s not just cell regrowth that is important, but also the way cells are organized to support organ function."
It is a daunting task—there is currently no medicine that can do what Dr Tancongco Culiat seeks to achieve.
“Current approaches, such as those based on stem cells, have shown the potential to restore tissue mass, but with only limited recovery of function," said acting NellOne CEO and Battelle Vantures General Partner Tracy Warren in the same article.
Heart attacks are usually recurrent, so if Dr Tancongco Culiat succeeds in her new undertaking, the product of her research will be the first medicine in the market that can do the most improvement to damaged heart tissues.
The potential is massive, and major institutions have invested an initial $1.5 million to fund Dr Tancongco Culiat’s work. NellOne Therapeutics, Inc. is a joint venture of Battelle Ventures, the University of Tennessee, and Oak Ridge National Laboratory (ORNL) which is under the United States Department of Energy.
JOANNA CAMILLE SISANTE, GMANews.TV
Comments